Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifioxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization

Clinical Therapeutics

Volumn 25, Issue 5, 2003, Pages 1453-1468

  Corrêa, João Carlos ^a,i   Badaró, Roberto ^b   Bumroongkit, Chaiwat ^c   Mera, Jorge Raúl ^d   Dolmann, Alberto Lorenzo ^e   Juárez Martínez, Luis Guillermo ^f   Mayrinck, Lusane Romero ^g   Tamez, Ricardo ^h   Yang, Joanna Y ^h  

^a Electrophysiology Section   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d Universidad del Aconcagua Argentina   (Argentina)

^e Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^g HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ NONE   (Brazil)

Author keywords

Ceftriaxone; Clarithromycin; Community acquired pneumonia; Erythromycin; Gatifloxacin; Tolerability

Indexed keywords

CEFTRIAXONE; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NAUSEA; PATHOGENESIS; PHLEBITIS; PNEUMONIA; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SPUTUM CULTURE; STANDARD; URTICARIA; VOMITING;

EID: 0038546888     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80132-7     Document Type: Article

References (20)

1. Bernstein JM. Treatment of community-acquired pneumonia - IDSA guidelines. Infectious Diseases Society of America. Chest. 1999;115(Suppl 3):9S-13S.
2. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994;18:501-513.
3. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-1729.
4. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993;148:1418-1426.
5. Luna CM, Ramirez J, López H, et al. ALAT (Latin American Thoracic Association) recommendations on community-acquired pneumonia [in Spanish]. Arch Bronconeumol. 2001;37:340-348.
6. Cubbon MD, Masterton RG. New quinolones - a fresh answer to the pneumococcus. J Antimicrob Chemother. 2000;46:869-872.
7. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1654-1659.
8. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;50:151-154.
9. Ramirez JA. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: Focus on switch therapy. Pharmacotherapy. 2001;21:79S-82S.
10. Milkovich G. Intravenous-to-oral transition therapy in community-acquired pneumonia: The INOVA Health System experience. Pharmacotherapy. 2001;21:83S-88S.
11. Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-446.
12. Perry CM, Ormrod D, Hurst M, Onrust SV. Gatifloxacin: A review of its use in the management of bacterial infections. Drugs. 2002;62:169-207.
13. Ramirez J, Nguyen T-H, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis. 1999;20(Suppl):S40-S48.
14. Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis. 1999;20(Suppl):S49-S59.
15. CFR §21.
16. CFR §21.
17. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: Wiley; 1981.
18. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347-382.
19. Fogarty C, Dowell ME, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis. 1999;20(Suppl):S60-S69.
20. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: Focus on respiratory infections. Drugs. 2002;62:13-59.